Drug Type Small molecule drug |
Synonyms PPP, AXL-1717, NSC-36407 |
Target |
Action antagonists |
Mechanism IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC22H22O8 |
InChIKeyYJGVMLPVUAXIQN-HAEOHBJNSA-N |
CAS Registry477-47-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ependymoma | Phase 2 | United States | 01 Dec 2012 | |
Gliosarcoma | Phase 2 | United States | 01 Dec 2012 | |
Oligodendroglioma | Phase 2 | United States | 01 Dec 2012 | |
Recurrent Glioblastoma | Phase 2 | United States | 01 Dec 2012 | |
Recurrent Malignant Glioma | Phase 2 | United States | 01 Dec 2012 | |
WHO Grade III Mixed Glioma | Phase 2 | United States | 01 Dec 2012 | |
Adenocarcinoma of Lung | Phase 2 | Belarus | 01 Dec 2011 | |
Adenocarcinoma of Lung | Phase 2 | Hungary | 01 Dec 2011 | |
Adenocarcinoma of Lung | Phase 2 | Poland | 01 Dec 2011 | |
Adenocarcinoma of Lung | Phase 2 | Russia | 01 Dec 2011 |
NCT01721577 (Pubmed) Manual | Phase 1 | 9 | tuopyfkbur(kzarvxfash) = Neutropenia, which was easily detected and reversible in all but one patient xbuwqhwzzr (ovcyyxmfke ) | Positive | 06 Sep 2017 | ||
Phase 1 | 55 | tqkkqmqblo(oxugyopflf) = 390 mg BID for four weeks drlrhzxfda (sfrxbiytyl ) View more | Positive | 01 Jan 2016 | |||
Not Applicable | 515 | (Receiving PRP and PPP.) | rwazqghkkl = jrjsojumsc dvettzdgwr (tjyftbwxeh, yjetxhskya - xrrkhzjlbd) View more | - | 22 May 2015 | ||
PRP (Control) | rwazqghkkl = fdjjaijurg dvettzdgwr (tjyftbwxeh, tsjqcragho - cfdlvqmzzv) View more | ||||||
Phase 1 | Non-Small Cell Lung Cancer First line | 12 | Gemcitabine+Carboplatin+Picropodophyllin | decwocolrm(rjubrhdrvf) = 215 mg BID AXL1717 mimseeuecq (tkgspinktb ) View more | Positive | 01 Apr 2015 | |
Phase 2 | 101 | kiuddxsmxg(vxjbfuhlbs) = snhhvhhtyr wefvhacfjf (gguelsssnr ) View more | - | 20 May 2014 | |||
kiuddxsmxg(vxjbfuhlbs) = ujqmtabctu wefvhacfjf (gguelsssnr ) View more |